Manufacture of Degarelix
The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, and processes for providing this lyophilized degarelix drug substance.
1. A method for modulating the viscosity of a degarelix drug substance, comprising:
a. purifying degarelix obtained by a liquid or solid phase peptide synthesis to obtain a degarelix solution with a purity of at least 95%, as determined by high-performance liquid chromatography (HPLC);
b. evaporating a solvent to concentrate the degarelix solution to obtain aggregated degarelix;
c. deaggregating the aggregated degarelix with acetic acid to obtain deaggregated degarelix; and
d. lyophilizing the deaggregated degarelix to provide a lyophilized degarelix drug substance,
wherein the lyophilized degarelix drug substance has a viscosity of up to 3.2 m Pas, as determined upon dissolution in an amount of 20 mg degarelix free base in 1 ml of water containing 2.5% (w/V) mannitol.
2. The method according to claim 1 , wherein the lyophilized degarelix drug substance is characterized by an acetic acid content ranging from 4.5% to 10% (w/w).
3. The method according to claim 1 , wherein the lyophilized degarelix drug substance is characterized by a water content ranging of 10% or less (w/w).
4. The method according to claim 1 , wherein the lyophilized degarelix drug substance shows an optical density of 0.10 AU or less at a concentration of 20 mg degarelix free base/ml in 2.5% (w/V) aqueous mannitol.
5. The method according to claim 1 , wherein the purity of the degarelix solution obtained in step (a) is at least 97.5%, as determined by HPLC.
6. The method according to claim 1 , wherein the evaporating of step (b) is carried out at or below 40° C.
7. The method according to claim 1 , wherein the deaggreagated degarelix obtained in step (c) has an acetic acid concentration ranging from 6% to 40% (v/v).
8. The method according to claim 1 , wherein step (c) is carried out over 1 to 15 hours.
9. The method according to claim 1 , wherein step (d) comprises a primary drying procedure and a secondary drying procedure, both of which are conducted at a pressure less than or equal to 0.5 mbar.
10. The method according to claim 9 , wherein the primary drying procedure is carried out at a primary drying temperature of about 20° C.
11. The method according to claim 9 , wherein the secondary drying procedure is carried out at a secondary drying temperature ranging from 15° C. to 25° C.
12. The method according to claim 1 , wherein step (d) is carried out over a period of about 5 days.
13. A method for modulating the viscosity of a degarelix drug substance, comprising:
a. purifying degarelix obtained by a liquid or solid phase peptide synthesis to obtain a degarelix solution with a purity of at least 95%, as determined by high-performance liquid chromatography (HPLC);
b. loading the degarelix solution onto a chromatographic column;
c. eluting degarelix from the column with acetic acid at a concentration in the range of 20 to 50 wt. % to provide eluted degarelix; and
d. lyophilizing the eluted degarelix to provide the degarelix drug substance,
wherein the lyophilized degarelix drug substance has a viscosity of up to 3.2 mPas, as determined upon dissolution in an amount of 20 mg degarelix free base in 1 ml of water containing 2.5% (w/V) mannitol.
14. The method according to claim 13 , wherein the acetic acid concentration in step c is in the range of 27 to 37 wt. %.
15. The method according to claim 13 , wherein the eluted degarelix is filtered prior to lyophilization.
16. A method for modulating the viscosity of a degarelix drug substance, comprising:
a. purifying degarelix obtained by a liquid or solid phase peptide synthesis to obtain a degarelix solution with a purity of at least 95%, as determined by high-performance liquid chromatography (HPLC);
b. adjusting the acetic acid concentration of the purified degarelix solution to 6 to 40% (w/w), if necessary; and
c. spray-drying the degarelix solution to provide the degarelix drug substance, wherein the degarelix drug substance has a viscosity of up to 3.2 mPas, as determined upon dissolution in an amount of 20 mg degarelix free base in 1 ml of water containing 2.5% (w/V) mannitol.